Do not get the "needle" here...30 Sep 2008 18:23
Having signed up three major pharamaceutical Cos recently, with more in the pipeline. Licence fees are expected to top £34mns by 2015. A Pre tax profit of just under £1mns penciled in with £2mns by 2010, This Co will develop its needleless syringe technology, to the point it will be come market leader, along with pre filled syringes, and humangrowth hormone delivery system being developed for Merck Serono. With several offers for the Co having been mooted, this stock is well undervalued on prospects.